Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The influence of different vasodilatators on blood pressure and intraocular pressure has been tested in animal experiments. For that purpose substances with alphasympathicolytic effect (Hydergin, Trental) have been tested as well as substances which are of direct influence on the muscles. In all cases a decrease of the blood pressure was noticed. Furthermore in most of the cases an increase of the intraocular pressure could be seen. This is due to a direct dilatation of ocular vessels. The effects were short-lived and reversible. We tried to find an explanation for the variations of intraocular pressure during the decrease of blood pressure. The low transmural pressure (PTM) and the corresponding low starting point of the muscle tonus seemed to be responsible for this phenomenon. Without doubt the starting point of the blood pressure, the dose, and the cardiac ability for compensation are of great influence in the development of the curve. Only a sufficiently high blood pressure is able to dilate the ocular vessels, so that one has to draw therapeutic conclusions from the constellation blood pressure/intraocular pressure before deciding on treatment.
 ...
PMID:[The influence of vasodilatators on intraocular pressure and blood pressure (author's transl)]. 30 21

A double-blind, placebo-controlled trial was carried out in 40 patients affected by multi-infarct dementia to see if a daily intravenous infusion of 3 mg co-dergocrine mesylate ('Hydergine') over 14 days would improve severely deteriorated elderly patients and shorten the latent period (3 months) which is observed when the drug is given orally. All the patients had severe mental impairment, psychological deficit or altered consciousness. A Hachinski score of 7 or more, and a cumulative score of at least 12 points on SCAG scale Items 1, 2 and 4 (anxiety/depression) and/or Items 5, 6 and 8 (alertness/confusion) were required for admission. After 1 week of intravenous infusion of placebo, patients were randomly allocated to treatment with co-dergocrine mesylate or placebo, from Day 1 to Day 14. The solutions were infused over a period of 2 hours. During the follow-up period from Day 15 to Day 21, the patients did not receive any treatment. Thirty-six patients (17 on co-dergocrine mesylate, 19 on placebo) completed the study. The results, as rated on the SCAG scale, indicated significant improvements, in favour of co-dergocrine mesylate, in cognitive dysfunction, mood depression, withdrawal and overall impression. Furthermore, the factor fatigue on the Nowlis scale and clinical global assessments by physicians also showed significant advantages of the co-dergocrine mesylate group over placebo. Nine out of 17 co-dergocrine mesylate patients complained of side-effects, usually experienced during infusion; they consisted mainly of nausea (6 patients), gastric discomfort (2 patients), and tremor, nasal congestion, flushing, hypotension and hypertension (1 patient each). Despite the appearance of side-effects, general tolerability was rated as 'good' by both physicians and patients. It is concluded, therefore, that intravenous high dose co-dergocrine mesylate treatment has a fast and clinically relevant effect on the key clinical symptoms of multi-infarct dementia.
 ...
PMID:Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial. 268 Feb 86

Bromocriptine and co-dergocrine (Hydergine R) reduce blood pressure and heart rate in experimental animals largely by stimulating DA2 receptors. A stimulant effect on DA1 receptors can be demonstrated in isolated tissues, but this action does not appear to make an important contribution to the depressor response to the two compounds, since effects are abolished by DA2 receptor blockade. Although both compounds are known to penetrate the brain, their antihypertensive effects, and the concomitant reductions in plasma noradrenaline levels produced in hypertensive patients can be prevented by domperidone, confirming a peripheral site of action. A review of the data available concerning the cardiovascular effects of bromocriptine and co-dergocrine in animals and man suggests that a DA2 receptor stimulant is effective in the treatment of hypertension.
 ...
PMID:Is stimulation of prejunctional dopamine receptors an antihypertensive principle? 330 28

Both age and hypertension are risk factors for the brain. In the presence of a multiple cerebral infarction as obtained by the intra-carotid injection of sodium arachidonate, Hydergine is capable, in the young and old, hypertensive or normotensive rat, of limiting the extent of the edematous reaction, to prevent the intra-cerebral accumulation of Ca++ ions, and limit the fall in cerebral blood flow, all of these facts resulting in a significant improvement in neuromotor behaviour.
 ...
PMID:[Cerebral blood flow and metabolism, and neurologic deficit in an experimental infarction. Application to the study of an ergot derivative]. 622 14

The antihypertensive efficacy of co-dergocrine mesylate (a mixture of dihydroergocornine mesylate, dihydroergocristine mesylate, and alpha- and beta-dihydroergocryptine mesylates; Hydergin) and its effects on heart rate, plasma catecholamines, catecholamine excretion and plasma prolactin was tested in 12 elderly hypertensive patients. Co-dergocrine mesylate (6 mg or 12 mg, 1 or 2 tablets once a day) caused a significant reduction of the blood pressure during rest and under physical stress without a reactive increase of the heart rate. Plasma norepinephrine and prolactin as well as urinary excretion of norepinephrine and epinephrine were not affected by co-dergocrine mesylate. The therapeutic advantage of co-dergocrine mesylate for the treatment of hypertension in the elderly is discussed.
 ...
PMID:[Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients]. 668 57